Arger NK, et al. - Since CXCL11 has shown unique functional properties in modulating adaptive immunity in model systems, therefore, researchers examined the link between serum levels of CXCL11 and clinical outcomes in a heterogeneous cohort of sarcoidosis subjects. Sarcoidosis subjects (n=104) had significantly elevated serum CXCL11 than healthy controls (n=49) in a cross-sectional analysis. A positive correlation of CXCL11 with CXCL9 and CXCL10, sedimentation rate, and mean expression of three interferon-gamma-related genes in whole blood (GBP1, STAT1, and STAT2) was found. Future pulmonary function test decline was predicted by CXCL11 levels. In the detection of patients that require longer-term monitoring for progressive thoracic and extra-thoracic sarcoidosis, serum CXCL11 could be helpful.